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http://dx.doi.org/10.1016/j.kjms.201
1607-551X/Copyright ª 2014, KaohsiuAbstract This study investigates the impact of general anesthesia (GA) on percutaneous
radiofrequency ablation (RFA) of hepatocellular carcinoma (HCC). A total of 118 treatment-
naı¨ve HCC patients in Barcelona Clinic Liver Cancer curative stage were enrolled. Patients
who underwent RFA with GA were designated as the GA group, and the others were identified
as the non-GA group. All the percutaneous RFA procedures were performed by the same hepa-
tologist. The GA group comprised 42 (44.1%) patients with 71 tumors (mean size, 2.53 cm) and
the non-GA group had 66 patients (55.9%) with 90 tumors (mean size, 2.35 cm). Complete tu-
mor ablation was achieved after one session in 92.3% of the 52 GA patients, and after one to
three sessions in 92.4% of 66 non-GA patients. The GA group required significantly fewer RFA
sessions to obtain a similar treatment effect (p < 0.001) and the duration of hospitalization
was also shortened among the GA patients (4.4  0.9 days vs. 5.1  1.9 days, p Z 0.044).
The 2-year overall survival and recurrence-free survival rates were not significantly different
between the two groups. Overall, performing RFA with GA can decrease the number of sessions
required to achieve complete tumor ablation in early stage HCC patients and shorten the hos-
pitalization duration.
Copyright ª 2014, Kaohsiung Medical University. Published by Elsevier Taiwan LLC. All rights
reserved.eclare no conflicts of interest.
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Hepatocellular carcinoma (HCC) is the fifth-most common
cancer in the world and the third-most common cause
of cancer mortality, accounting for approximately
600,000e700,000 deaths/year [1,2]. Liver transplantation,
surgical resection, and local ablation are currently recog-
nized as potentially curative treatment modalities by both
Eastern and Western medicine practice guidelines [3e5].
Liver transplantation is unfeasible in Asian countries due to
the limited availability of liver donors. Although surgical
resection can achieve better overall survival rates and
lower rates of recurrence post-treatment, the procedure
can be risky for patients who have relatively poor hepatic
functional reserve [6e9]. Local ablation methods, such as
percutaneous radiofrequency ablation (RFA), percutaneous
ethanol injection (PEI), and acetic acid injection are rela-
tively safe options for treating small HCC lesions in patients
who are not eligible for liver transplantation or surgical
resection [10e12].
Overall, RFA is a superior technique when compared
other methods of local ablation, resulting in better tumor
control and higher survival rates and at the same time
requiring fewer post procedure therapy sessions [13e16].
Therefore, RFA is now the local ablation method of choice
for small HCCs in clinical practice. Percutaneous RFA pro-
cedures have traditionally been performed under local
anesthesia and sedation. However, some patients have
experienced severe pain and anxiety that prevent the
completion of the procedure, which resulted in an insuffi-
cient tumor ablation area. The local recurrence rate can
differ significantly between patients who had achieved a
sufficient ablation area and those who did not [17,18].
Therefore, ensuring sufficient tumor ablation during RFA is
crucial in optimizing the treatment effect. In contrast to
local anesthesia, general anesthesia (GA) can induce
deeper sedation and better analgesia in patients undergo-
ing the RFA procedure. However, the outcome benefit of GA
during RFA for treatment of HCC is yet to be determined.
This study aimed to elucidate the impact of GA, as opposed
to other anesthesia methods, on the effectiveness of
percutaneous RFA for treatment of Barcelona Clinic Liver
Cancer (BCLC) curative stage HCC.
Patients and methods
Patients
The protocol for this retrospective study was approved by
the Ethics Committee of Kaohsiung Chang Gung Memorial
Hospital (Kaohsiung, Taiwan), a tertiary medical center for
HCC treatment. A total of 118 treatment-naı¨ve patients
with BCLC curative stage (including very early/early stage)
HCC patients who had underwent percutaneous RFA per-
formed by a single hepatologist (J.H.W.), between January
2005 and December 2010, as the initial treatment option
were enrolled into this study. The first RFA procedure under
GA was performed in November 2007. Patients who under-
went GA and those who received epidural or local anes-
thesia were defined as the GA group and non-GA group,
respectively. The type of anesthesia used was determinedfor each case by the clinician’s suggestions and the pa-
tient’s preferences. The diagnosis of HCC was based on the
criteria of the practice guidelines of the European Associ-
ation for the Study of the Liver or the American Association
for the Study of Liver Disease [3,4]. The patients’ de-
mographic and clinical characteristics, initial HCC treat-
ment options, HCC recurrence results, and survival data
were retrospectively collected from the medical records.
RFA techniques
RFA was performed with the Cool-Tip radiofrequency sys-
tem (Radionics, Burlington, MA, USA), under real-time USA
guidance, using a 17-gauge, 2-cm or 3-cm, cooled-tip
electrode connected to a generator. Temperature and tis-
sue impedance were monitored during ablation. A tip
temperature of 10e20C was maintained by infusion of
chilled water. Radiofrequency energy was delivered for
6e12 minutes for each application. Multiple overlapping
ablation zones were required when treating large lesions.
Anesthesia methods
GA was induced with 1 mg/kg fentanyl, 1.5e2 mg/kg pro-
pofol, and 0.2 mg/kg cisatracurium and maintained with
2e2.5% sevoflurane in an air/oxygen mixture. An endo-
tracheal tube and ventilator support were inserted into
the patient in the operating room to provide a stable
respiratory pattern during RFA. When epidural anesthesia
was used, the epidural catheter was usually inserted
preoperatively at a thoracic level (T7e8 or T8e9), and
10 mL of 0.3% ropivacaine was administered via the
epidural catheter approximately 20 minutes before the
RFA procedure. Fentanyl was administered when patients
experienced referred pain. When local anesthesia was
used, a 10 mL dose of 2% xylocaine was injected subcu-
taneously into the planned RFA puncture site. In addition,
50 mg of Demerol was administered intramuscularly or
intravenously prior to RFA.
Assessment of treatment efficacy and follow-up
The tumor response to RFA was assessed by computed to-
mography (CT), which is a standard imaging modality that
was performed 1 month after ablation. Complete tumor
response was defined as the complete absence of contrast
enhancement of all known lesions upon radiological exam-
ination. All patients were followed up for tumor recurrence
by liver ultrasonography for every 2e3 months and
enhanced CT for every 6e12 months until either the pa-
tient’s death or loss of contact with the outpatient service.
Local tumor recurrence was defined as the appearance of a
new lesion within 1 cm of the initial tumor. Intrahepatic
tumor recurrence was defined as a new lesion at a site 2 cm
away from the initial tumor. The treatment for recurrent
tumors was chosen based on the patient’s preferences and
the clinicians’ clinical judgment. Intrahepatic recurrences
were treated by curative modalities such as RFA, PEI, and
transcatheter arterial embolization. All patients were fol-
lowed up until death or by the end of December 2011.
Table 1 Baseline characteristics and clinical outcomes of
the 118 enrolled patients.
GA group,
n Z 52
Non-GA
group, n Z 66
p
Age (y) 64.7  11.7 63.7  10.7 0.337
Sex
Male 37 (71.2) 42 (63.6) 0.389
Female 15 (28.8) 24 (36.4)
HBV infection
Yes 16 (30.8) 24 (36.4) 0.336
No 36 (69.2) 42 (63.6)
HCV infection (þ)
Yes 33 (63.5) 40 (60.6) 0.751
No 19 (36.5) 26 (39.4)
Comorbid disease (þ)a
Yes 36 (69.2) 46 (69.7) 0.956
No 16 (30.8) 20 (30.3)
ChildePugh classification
A 44 (84.6) 58 (87.9) 0.607
B 8 (15.4) 8 (12.1)
Number of tumors
1 34 (65.4) 48 (72.7) 0.073
2 17 (32.7) 12 (18.2)
3 1 (1.9) 6 (9.1)
Tumor size (cm) 2.53  0.8 2.36  0.7 0.315
BCLC stage
Very early 13 (25) 18 (27.3) 0.781
Early 39 (75) 48 (72.7)
Difficult site (þ)b 14 (26.9) 13 (19.7) 0.354
Sessions of ablation
1 52 (100) 53 (80.3) 0.003
2 0 12 (18.2)
3 0 1 (1.5)
Mean session of
ablation
1 1.2  0.4 <0.001
Duration of ablation
(min)
24.1  8.8 16  6.1 0.001
Hospital stay (d) 4.4  0.9 5.1  1.9 0.044
Complication
Yes 0 1 (1.5) 0.373
No 52 (100) 65 (98.5)
Complete tumor necrosis
Yes 48 (92.3) 61 (92.4) 0.981
No 4 (7.7) 5 (7.6)
Tumor recurrence
Yes 30 (57.7) 48 (72.7) 0.087
No 22 (42.3) 18 (27.3)
Local tumor recurrence
Yes 13 (25) 25 (37.9) 0.137
No 39 (75) 41 (62.1)
Mortality
Yes 8 (15.4) 18 (27.3) 0.122
No 44 (84.6) 48 (72.7)
Data are presented as n (%) or mean  SD.
BCLC Z Barcelona Clinic Liver Cancer; GA Z general anes-
thesia; HBV Z hepatitis B virus; HCV Z hepatitis C virus.
a Comorbid disease means patients have diseases including one
of renal disease,diabetesmellitus,hypertension,or heartdisease.
b Difficult site refers to a site where it is difficult for a needle
to approach or where it may be easy to lead to trauma of
adjacent organs or vessels.
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Data are expressed as the mean  standard deviation.
Categorical data and continuous data were compared using
Fisher’s exact and Student t test, respectively. Cumulative
and disease-free survival rates were calculated by the
KaplaneMeier method, and the differences between the
two groups’ survival curves were statistically compared
with log-rank test. Univariate and multivariate analyses of
the factors associated with overall survival and tumor
recurrence were performed using the Cox regression
model. Statistical analyses were performed using SPSS
version 17.0 for Windows (SPSS, Inc., Chicago, IL, USA). All
p values 0.05 were accepted as statistically significant.
Results
Patients
The GA group consisted of 52 patients (44.1%) and the non-
GA group of 66 patients (55.9%). Out of the 66 non-GA pa-
tients, 34 of whom received local anesthesia and 32
epidural anesthesia. Cumulatively, the GA group comprised
71 tumors with a mean size of 2.53 cm and the non-GA
group had 90 tumors with a mean size of 2.36 cm. The
baseline characteristics, including age, sex, presence of
comorbidities, BCLC stage classification, ChildePugh clas-
sification, presence of hepatitis B or C virus infection, or
tumor at a traditionally difficult ablation site (Table 1) did
not differ significantly between the groups. Patients in the
GA group obtained the same complete tumor necrosis rate
compared with those in the non-GA group (92.3% vs. 92.4%,
p Z 0.981), However, the significantly fewer RFA sessions
were required for complete tumor ablation for the GA
group (1 session vs. 1.2  0.4 session, p < 0.001). Addi-
tionally, the duration of hospital stay in the GA group was
also significantly shorter than that in the non-GA group
(4.4  0.9 days vs. 5.1  1.9 days, p Z 0.044). No com-
plications were observed after the RFA procedure in either
group, except for one non-GA patient who developed right
massive pleural effusion on the day following the RFA pro-
cedure. Thoracocentesis was performed on this patient and
the pleural effusion was drained.
Overall and recurrence-free survival
The 1- and 2-year recurrence-free survival (RFS) and overall
survival (OS) rates did not differ significantly between the
two groups (1- and 2-year RFS: 64.3% and 37.6% for the GA
group vs. 66.2% and 44.2% for the non-GA group; 1- and 2-
year OS: 94.2% and 89.3% for the GA group vs. 97% and 90.9%
for the non-GA group; Figures 1 and 2A). The 1- and 2-year
local RFS rates were also similar between the two groups
(1- and 2-year local RFS: 82.1%, and 69.6% in the GA group vs.
90.8% and 71.5% in the non-GA group, pZ 0.872; Figure 2B).
Factors associated with tumor recurrence and
patient survival
The univariate analysis showed that only a serum a-feto-
protein (AFP) level >200 ng/mL is an independent factor
Figure 1. The comparison of cumulative overall survival
between general anesthesia (GA) and non-GA groups. The 2-
year overall survival rates were 89.3% in the GA group, and
90.9% in the non-GA group (p Z 0.203).
Figure 2. (A) Comparison of recurrence-free survival (RFS)
between general anesthesia (GA) and non-GA groups. The 2-
year RFS rates were 37.6% in the GA group, and 44.2% in the
non-GA group (p Z 0.563). (B) Comparison of local RFS rates
between GA and non-GA groups. The 2-year local RFS rates
were 69.6% in the GA group, and 71.5% in the non-GA group
(p Z 0.872).
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cated that patients who achieved complete tumor necrosis
had better rates of survival. Furthermore, an AFP level
>200 ng/mL and a class A ChildePugh score were signifi-
cantly associated with tumor recurrence (Tables 2 and 3).
Neither the univariate nor multivariate analysis showed any
significant difference in mortality or tumor recurrence be-
tween GA and non-GA patients.
Discussion
For HCC lesion patients who are ineligible for liver trans-
plantation or surgical resection, RFA is currently the first
choice for local ablation [10e12]. The 2-year OS rate of
patient who received RFA is reported to range from 88% to
96%, and the 2-year RFS rate from 40% to 70% [19e21]. The
RFS and OS rates of our cohort of patients with BCLC
curative-stage HCC who underwent RFA were comparable
to those reported by other published studies, regardless of
GA use.
Several anesthesia methods, including local, epidural,
and GA, can be used to control pain in HCC patients un-
dergoing RFA. The choice of the anesthesia method is
depended upon the clinician’s recommendation and the
patient’s preference. Referred pain due to thermal injury is
often the main problem during RFA procedures performed
under local anesthesia [22]. Severe pain may occasionally
induce pain shock or bradycardia, which can force the
operator to shorten the duration of ablation, decrease the
current intensity, or reduce the amount of overlapping
ablations [23]. Epidural anesthesia is a partial solution to
reduce the pain experienced during RFA procedures; how-
ever, it is an invasive technique and the skill required for
thoracic spinal puncture can limit its use. By contrast, un-
dergoing a total RFA procedure while clearly conscious,
with the trunk numbed, might cause some patients to
develop phobia or panic, which can also lead to an incom-
plete treatment. Thus, the deep sedation afforded by GA
can avoid this influence of pain and panic during RFA pro-
cedures. Another advantage of GA is that it can reduce the
systolic blood pressure, decrease the hepatic blood flow,and therefore increase the ablation diameter [24,25].
However, as GA carries a major risk of myocardial infarc-
tion, stroke, or malignant hyperthermia, willing patients
still require a strict evaluation of anesthesia risk prior to
the procedure.
Some studies have shown that anesthetic techniques
may potentially affect the long-term outcomes of cancer
surgery [26,27]. For RFA of small HCC, Lai et al. [28]
reported that anesthetic technique was a significant pre-
dictor of recurrence-free survival under the Cox regression
model [hazard ratio, 3.66 (95% confidence interval
2.59e5.15); p < 0.001], and suggested that patients who
underwent RFA of small HCC lesions with GA were at
reduced risks for cancer recurrence relative to those who
underwent RFA with epidural anesthesia. In this study, we
found that variance of anesthetic technique has no effect
on the 2-year overall and local recurrence rates. The initial
rates of complete tumor necrosis were similar between our
GA and non-GA groups, which led to comparable rates of
tumor recurrence during follow-up. This similarity may
have diluted the impact of the anesthetic technique on HCC
recurrence in our study. The multivariate analysis also
confirmed this finding by indicating that only a serum AFP
level >200 ng/mL and a class A ChildePugh score are the
Table 2 Multivariate analysis of factors associated with liver disease related mortality.
Univariate Multivariate
HR (95% CI) p HR (95% CI) p
Age (per 1 y increase) 1.01 (0.98e1.05) 0.399
Male vs. female 1.1 (0.54e2.21) 0.796
HBV infection
Yes vs. no 1.11 (1.45e8.55) 0.918
HCV infection
Yes vs. no 0.67 (0.34e1.31) 0.237
ChildePugh class
B vs. A 1.94 (0.88e4.3) 0.103
BCLC stage
Early vs. very early 1.32 (0.57e3.03) 0.517
Serum AFP (ng/mL)
200 vs. <200 2.67 (1.24e5.73) 0.012
Tumor size (per 1 cm increase) 1.14 (0.73e1.77) 0.571
Comorbid diseasea
Yes vs. no 1.35 (0.63e2.89) 0.44
GA vs. non-GA 1.62 (0.77e3.43) 0.207
Complete tumor necrosis
Yes vs. no 0.42 (0.16e1.07) 0.075 0.26 (0.08e0.86) 0.028
Tumor recurrence
Yes vs. no 1.4 (0.63e3.11) 0.404
BCLCZ Barcelona Clinic Liver Cancer; CIZ confidence interval; GAZ general anesthesia; HBVZ hepatitis B virus; HCVZ hepatitis C
virus; HR Z hazard ratio.
a Comorbid disease means patients have other diseases including one of renal disease, diabetes mellitus, hypertension, or heart
disease.
RFA under general anesthesia 563major contributor of recurrence. A higher serum AFP level
has been reported to be associated with HCC recurrence in
previous studies [18,19]. Most of the patients in our study
cohort scored as ChildePugh class A (102 out of 118, 86.4%),Table 3 Multivariate analysis of factors associated with hepato
Univariat
HR (95% CI)
Age (per 1 y increase) 1 (0.98e1.02)
Male vs. female 1.04 (0.66e1.66)
HBV infection
Yes vs. no 2.15 (0.29e15.8)
HCV infection
Yes vs. no 1.12 (0.71e1.78)
ChildePugh class
B vs. A 0.6 (0.29e1.24)
BCLC stage
Early vs. very early 1.53 (0.88e2.65)
Serum AFP (ng/mL)
200 vs. <200 1.64 (0.86e3.1)
Tumor size (per 1 cm increase) 1.3 (0.96e1.75)
Comorbid diseasea
Yes vs. No 1.19 (0.73e1.94)
GA vs. non-GA 1.15 (0.88e2.65)
Complete tumor necrosis
Yes vs. no 0.87 (0.38e2.04)
BCLCZ Barcelona Clinic Liver Cancer; CIZ confidence interval; GAZ
virus; HR Z hazard ratio.
a Comorbid disease means patients have other diseases including onewhich may have over-weighted the comparison with
ChildePugh class B for tumor recurrence.
In this study, all patients received initial RFA treatment
by a single experienced hepatologist (J.H.W.) from Januarycellular carcinoma recurrence.
e Multivariate
p HR (95% CI) p
0.77
0.86
0.45
0.62 0.37 (0.15e0.87) 0.023
0.17
0.134
0.132 2.52 (1.17e5.41) 0.018
0.085
0.49
0.134
0.75
general anesthesia; HBVZ hepatitis B virus; HCVZ hepatitis C
of renal disease, diabetes mellitus, hypertension, or heart disease.
564 Y.-H. Kuo et al.2005 to December 2010. The first RFA performed with GA
was done in November 2007, and most of the initial RFA
procedures (52 out of 61, 85.2%) were performed under GA
from that point onward. The baseline characteristics of the
patients, which include age, sex, tumor etiology, presence
of comorbidities, BCLC stage classification, hepatic func-
tional reserve, and tumor size were not significantly
different between our GA and non-GA groups. The duration
of each RFA session was longer in our GA group due to the
deeply sedative effect of GA. All of the patients in our GA
group required only one session of the procedure to com-
plete the treatment, whereas 12 of those in the non-GA
group required one additional session; and one needed two
additional sessions during the same hospital say. Further-
more, our GA patients were endotracheally intubated and
their respiration patterns were ventilator-controlled during
RFA. The intubation allowed the operator to position the
RFA needle electrode more accurately, due to the longer
time intervals between each breath. This phenomenon may
explain the fact that our GA group required fewer treat-
ment sessions than the non-GA group. Our study also
demonstrated the safety of the RFA procedures. Only one
patient in the non-GA group in our study had a major
postoperative complication, developing right pleural effu-
sion on the following day, which was resolved by thor-
acocentesis. Both the GA and non-GA groups of our HCC
cohort experienced complete tumor necrosis rates as high
as 92%, as determined 1 month later by CT. Additional
sessions of RFA performed in the non-GA group led to the
equivalent treatment effects observed between the
groups. Furthermore, the duration of hospital stay required
was also prolonged in the non-GA group, which might in-
crease the hospitalization cost of the treatment.
Similar to the findings reportedbyLai et al. [28], the 2-year
survival rates were comparable between our two groups. The
HCC recurrence was treated by consecutive treatment mo-
dalities such as RFA, PEI, and transcatheter arterial emboli-
zation (TAE), chosen according to the tumor status and
patient’s preference. Aggressive control of intrahepatic
recurrence produced acceptable OS in our HCC cohort, which
was irrespective of whether the initial RFA was performed
under GA or not. Multivariate analysis of associated factors
showed that the patients in our study who did not achieve
complete tumor necrosis in the initial RFA had a lowerOS rate.
Our study had certain limitations. First, although all
patients were treated by a single hepatologist, the anes-
thesia technique was not assigned randomly. This is due to
the fact that random assignment of anesthesia technique
without consulting the patient’s preference is an ethical
issue in clinical practices. A large-scale, multicenter, and
prospective trial could resolve this problem. Furthermore,
our GA in RFA treatment was only performed since
November 2007, almost 3 years after the first RFA proce-
dure performed with other analgesic methods. This
calendar-year bias allowed us to compare only up to the 2-
year rates of RFS and OS. Longer observation is necessary to
obtain more complete and meaningful comparisons.
In summary, the use of deep sedation during percuta-
neous RFA for treatment of BCLC curative-stage HCC did
not affect the 2-year OS or RFS rates in our cohort. How-
ever, the patients undergoing RFA with GA required fewer
sessions to obtain an equivalent complete response thanthose with partial or no sedation. Moreover, the duration of
hospitalization can be further shortened for patients un-
dergoing RFA with GA. Therefore, GA is an appropriate HCC
treatment option for avoiding referred pain and panic in
patients undergoing percutaneous RFA.
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